Telix announced final results from the IPAX-1 Ph I/II study of TLX101 therapy

Telix Pharmaceuticals Limited (ASX: TLX) announced final results from the IPAX-1 Ph I/II study of TLX101 therapy along with external beam radiation therapy (EBRT) in recurrent glioblastoma multiforme.

Objectives:

• The key objective of the IPAX-1 study was to assess the safety as well as tolerability profile of intravenous 131I-IPA administered alongside second line EBRT in patients with recurrent glioblastoma multiforme.
• Secondary objectives of the study were to determine ideal dosing, biodistribution along with radiation absorption into the tumour, as well as evaluate initial efficacy via clinical and imaging-based assessment of tumour response.

Outcome:

Final data up to the conclusion of the post-study follow-up period confirmed that the study has met its key objective, representing the safety & tolerability profile of TLX101 at the dosing range tested.

• The study provided encouraging preliminary efficiency data for more assessment, indicating a median total survival of 13 months from the start of treatment in the recurring setting, or 23 months from initial diagnosis.
• Given that glioblastoma multiforme has a median survival from initial diagnosis of 12-15 months, the total survival improvement trend seen in this patient population clearly warrants more assessment in a larger patient population.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au